SRX GLOBAL ANNOUNCES ACTIVATION OF THE UNIVERSITY OF CALIFORNIA, DAVIS AS A CLINICAL TRIAL SITE FOR CERO THERAPEUTICS’ ONGOING PHASE 1 CERTAIN-T TRIAL OF CER-1236 IN HEMATOLOGIC MALIGNANCIES

Reuters · 4d ago

Please log in to view news